Ind-Swift Labs Q2 FY27: Consolidated revenue Rs 240.46 cr, PAT Rs 34.22 cr
For the quarter ended 30.09.2026, consolidated revenue rose to Rs 240.46 cr and PAT to Rs 34.22 cr from Rs 158.64 cr and Rs 7.99 cr a year earlier.
Key takeaways
- Revenue from operations Rs 240.46 cr vs Rs 158.64 cr a year earlier
- Total Income Rs 248.06 cr vs Rs 170.50 cr in the corresponding quarter
- PAT from continuing operations Rs 34.22 cr vs Rs 7.99 cr a year ago
- Basic EPS 3.94 vs 1.00 in the corresponding quarter last year
- Total expenses Rs 201.11 cr vs Rs 160.16 cr in Q2 FY26
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 240.46 cr | Rs 158.64 cr | +51.6% |
| PAT | Rs 34.22 cr | Rs 7.99 cr | +328.3% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 14.23% of revenue, up 919 bps from 5.04%.
- Revenue rose 51.6% while total expenses rose 25.6%.
- Cost of materials accounted for Rs 26.77 cr of the Rs 40.95 cr rise in total expenses (65%).
- Cost of materials took 38.6% of revenue, against 41.7% a year earlier.
Key numbers (consolidated, Rs in Lakhs)
From the statement of consolidated unaudited financial results for the quarter ended 30.09.2026, compared with the corresponding quarter ended 30.09.2025:
- Revenue from operations: Rs 240.46 cr (Q2 FY27) vs Rs 158.64 cr (Q2 FY26)
- Other Income: Rs 7.60 cr vs Rs 11.86 cr
- Total Income: Rs 248.06 cr vs Rs 170.50 cr
- Cost of Materials Consumed: Rs 92.87 cr vs Rs 66.10 cr
- Purchase of stock in Trade: Rs 16.14 cr vs Rs 11.89 cr
- (Increase) /decrease in FG,WIP & stock in trade: Rs (2.50) cr vs Rs (0.3472) cr
- Employee benefit: Rs 37.97 cr vs Rs 36.27 cr
- Finance Costs: Rs 1.33 cr vs Rs 2.01 cr
- Depreciation: Rs 7.77 cr vs Rs 6.98 cr
- Other expenditure: Rs 50.51 cr vs Rs 37.25 cr
- TOTAL EXPENSES: Rs 201.11 cr vs Rs 160.16 cr
- Profit(loss) before exceptional Items and Tax: Rs 43.96 cr vs Rs 10.34 cr
- Exceptional Items (Income) /loss: Rs 0.5797 cr vs Rs 0.00 cr
- Profit(loss) before Tax (After exceptional items): Rs 43.38 cr vs Rs 10.34 cr
- Current Tax: Rs 9.23 cr vs Rs 2.30 cr
- Deferred Tax: Rs 0.00 cr vs Rs 0.00 cr
- Profit/ (Loss) after tax and before share of: Rs 34.15 cr vs Rs 8.04 cr
- Share of profit (loss) in joint venture: Rs 0.0719 cr vs Rs (0.0529) cr
- Profit (+)/ Loss (-) for the period from continuing operations: Rs 34.22 cr vs Rs 7.99 cr
- Net Profit / (Loss) for the period after tax & Exceptional items: Rs 34.22 cr vs Rs 7.99 cr
- Other Comprehensive income (Loss) for the period , net of Tax: Rs (2.87) cr vs Rs 0.00 cr
- Total Comprehensive Income for the Period: Rs 31.35 cr vs Rs 7.99 cr
- Paid up Equity Share Capital (Face Value of Rs. 10/- per Share): Rs 86.96 cr vs Rs 81.61 cr
- EPS (of Rs. 10/- each) (Not annualised) – Basic: 3.94 vs 1.00
- EPS (of Rs. 10/- each) (Not annualised) – Diluted: 3.92 vs 0.96
In the quarter ended 30.09.2026, consolidated revenue from operations and total income increased versus the same quarter in the previous year, with higher cost of materials consumed, purchases of stock in trade, employee benefits and other expenditure also reported in the statement of financial results. Profit before tax after exceptional items, profit after tax and earnings per share were higher year-on-year on a consolidated basis, as per the figures presented in the statement of consolidated unaudited financial results.
Track Ind-Swift Laboratories Ltd
Cruxal reads every Ind-Swift Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.